Halozyme Therapeutics (NASDAQ:HALO) Price Target Raised to $130.00

Halozyme Therapeutics (NASDAQ:HALO) had its target price upped by TD Cowen from $105.00 to $130.00 in a report released on Tuesday, Benzinga reports. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. TD Cowen’s target price would indicate a potential upside of 18.72% from the company’s previous close.

A number of other analysts also recently commented on HALO. Wall Street Zen upgraded shares of Halozyme Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 8th. Citizens Jmp upped their target price on Halozyme Therapeutics from $92.00 to $93.00 and gave the company a “market outperform” rating in a report on Friday, August 7th. HC Wainwright increased their price target on Halozyme Therapeutics from $115.00 to $130.00 and gave the company a “buy” rating in a research report on Wednesday, October 7th. Citigroup reissued a “market outperform” rating on shares of Halozyme Therapeutics in a research note on Friday, August 7th. Finally, Leerink Partners upgraded Halozyme Therapeutics from a “market perform” rating to an “outperform” rating and boosted their price objective for the stock from $83.00 to $110.00 in a report on Friday, August 7th. Nine investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $96.50.

Halozyme Therapeutics Stock Performance

Halozyme Therapeutics stock traded down $1.58 during mid-day trading on Tuesday, hitting $109.50. 830,748 shares of the company’s stock traded hands, compared to its average volume of 1,926,646. Halozyme Therapeutics has a one year low of $61.22 and a one year high of $116.85. The firm has a 50 day moving average price of $106.78 and a 200 day moving average price of $83.54. The company has a quick ratio of 2.31, a current ratio of 2.71 and a debt-to-equity ratio of 13.50. The company has a market cap of $12.43 billion, a PE ratio of 32.65, a price-to-earnings-growth ratio of 0.42 and a beta of 0.88.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.79 by $0.49. Halozyme Therapeutics had a net margin of 24.86% and a return on equity of 260.98%. The business had revenue of $481.00 million during the quarter, compared to analysts’ expectations of $402.28 million. During the same period last year, the firm posted $1.54 earnings per share. The business’s revenue was up 47.7% on a year-over-year basis. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. On average, equities analysts forecast that Halozyme Therapeutics will post 8.25 EPS for the current year.

Insider Transactions at Halozyme Therapeutics

In other Halozyme Therapeutics news, Director Bernadette Connaughton sold 1,626 shares of the firm’s stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $102.80, for a total transaction of $167,152.80. Following the transaction, the director directly owned 40,418 shares in the company, valued at $4,154,970.40. This trade represents a 3.87% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 20,000 shares of the firm’s stock in a transaction that occurred on Thursday, October 8th. The shares were sold at an average price of $109.40, for a total value of $2,188,000.00. Following the completion of the transaction, the chief executive officer directly owned 767,780 shares in the company, valued at $83,995,132. The trade was a 2.54% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 125,852 shares of company stock valued at $13,538,046 in the last three months. Corporate insiders own 2.50% of the company’s stock.

Hedge Funds Weigh In On Halozyme Therapeutics

A number of institutional investors have recently modified their holdings of HALO. CoreCap Advisors LLC lifted its position in Halozyme Therapeutics by 98.0% during the 3rd quarter. CoreCap Advisors LLC now owns 303 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 150 shares during the last quarter. MidFirst Bank acquired a new stake in shares of Halozyme Therapeutics in the second quarter valued at about $27,000. Mitsubishi UFJ Asset Management Co. Ltd. bought a new position in shares of Halozyme Therapeutics in the second quarter worth about $28,000. Quantbot Technologies LP bought a new position in Halozyme Therapeutics in the 2nd quarter worth approximately $30,000. Finally, Caitlin John LLC bought a new position in Halozyme Therapeutics in the 2nd quarter worth approximately $44,000. Institutional investors own 97.79% of the company’s stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing drug-delivery technologies that improve the administration of injectable medicines. The company’s primary platform, ENHANZE, uses recombinant human hyaluronidase to temporarily modify tissue beneath the skin, allowing certain drugs and biologics that are traditionally delivered by intravenous infusion to be administered by subcutaneous injection.

Halozyme licenses its technology to pharmaceutical and biotechnology companies, which incorporate it into their own therapies.